The antitumoral compound Kahalalide F acts on cell lysosomes.
The target for the antitumoral peptidic drug, Kahalalide F, has been studied in cultured cells. In the presence of the compound, the cells became impressively swollen, showing the formation of large vacuoles. The formation of these vacuoles appears to be the consequence of changes in lysosomal membranes. Thus, lysosomes are a target for Kahalalide F action.
García-Rocha
M
M
Centro de Biología Molecular, Universidad Autónoma de Madrid, Spain.
Bonay
P
P
Avila
J
J
D000595:Amino Acid Sequence; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D002522:Chlorocebus aethiops; D006224:Cricetinae; D047630:Depsipeptides; D004721:Endoplasmic Reticulum / Q000187:drug effects; D006056:Golgi Apparatus / Q000187:drug effects; D006367:HeLa Cells; D006801:Humans; D007668:Kidney / Q000166:cytology / Q000187:drug effects / Q000648:ultrastructure; D008247:Lysosomes / Q000187:drug effects*; D008969:Molecular Sequence Data; D010455:Peptides / Q000494:pharmacology*; D051381:Rats; D013347:Subcellular Fractions / Q000187:drug effects; D014709:Vero Cells
D000970:Antineoplastic Agents; D047630:Depsipeptides; D010455:Peptides; C097897:kahalalide F